Literature DB >> 6625536

Regional blood flow in ethylnitrosourea-induced brain tumors.

R G Blasberg, T Kobayashi, M Horowitz, J M Rice, D Groothuis, P Molnar, J D Fenstermacher.   

Abstract

Regional blood flow was measured in experimental brain tumors using iodoantipyrine labeled with carbon 14 and quantitative autoradiography. A total of fifteen oligodendrogliomas, sixteen mixed gliomas, one astrocytoma, one ependymoma, and three malignant schwannomas were studied in 9 rats. The mean tumor blood flows for all glioma classifications were similar, averaging 45 +/- 3 (standard error of the mean) ml . hg-1 . min-1. Flow was fairly uniform within individual oligodendrogliomas and there was no apparent correlation between blood flow and tumor size or location. The mixed gliomas were larger than the oligodendrogliomas and had a wider range of blood flow. Small focal areas of necrosis were observed in 7 mixed gliomas, and low flows were usually measured in these regions; these flows were not always the lowest regional values measured within the mixed gliomas or total group of tumors, however. Small tumor regions with increased vascularity, frequently with endothelial cell proliferation, were observed in oligodendrogliomas and to a greater extent in mixed gliomas; these regions were correlated with small elevations in blood flow (10 to 15 ml . hg-1 . min-1) in comparison with surrounding tumor tissue. Brain adjacent to tumor usually had higher blood flows than that in tumor periphery. Hemispheric differences in blood flow related to the site of primary tumor growth were not observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6625536     DOI: 10.1002/ana.410140206

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

Authors:  Claudia Weidensteiner; Wilfried Reichardt; Paul J Shami; Joseph E Saavedra; Larry K Keefer; Brunhilde Baumer; Anna Werres; Robert Jasinski; Nadja Osterberg; Astrid Weyerbrock
Journal:  Nitric Oxide       Date:  2013-01-28       Impact factor: 4.427

Review 2.  Vascular microenvironment in gliomas.

Authors:  P Vajkoczy; M D Menger
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 3.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

Authors:  G Thompson; S J Mills; D J Coope; J P B O'Connor; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

5.  Regional glucose utilization and blood flow in experimental brain tumors studied by double tracer autoradiography.

Authors:  A Kato; K Sako; M Diksic; Y L Yamamoto; W Feindel
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

6.  Modification of tumor blood flow and enhancement of therapeutic effect of ACNU on experimental rat gliomas with angiotensin II.

Authors:  K Tokuda; H Abe; T Aida; S Sugimoto; S Kaneko
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

7.  Noisy intracranial tumours.

Authors:  B T van Dooren; A C van Bruggen; J J Mooij; J M Hew; H L Journée
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Murine sarcoma virus-induced brain tumors. Concurrent measurements of blood flow and transcapillary transport.

Authors:  F J Vriesendorp; D R Groothuis; N A Vick
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

Review 9.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

10.  Blood flow in an experimental rat brain tumor by tissue equilibration and indicator fractionation.

Authors:  M M Graham; A M Spence; G L Abbott; L O'Gorman; M Muzi
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.